{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:11:41Z","timestamp":1791173501792,"version":"4.1.0"},"publisher-location":"Chichester, UK","reference-count":129,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd008870","type":"reference-entry","created":{"date-parts":[[2010,11,29]],"date-time":"2010-11-29T19:57:44Z","timestamp":1291060664000},"source":"Crossref","is-referenced-by-count":35,"title":["Aminosalicylates for induction of remission or response in Crohn's disease"],"prefix":"10.1002","author":[{"given":"Wee-Chian","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Hanauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,12,8]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD008870-BIB1|cit1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1542-3565(04)00122-3","article-title":"Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1002\/14651858.CD008870-BIB2|cit2","unstructured":"Hoechst Marion Roussel Inc Clinical study report: efficacy and safety of oral Pentasa in the treatment of active Crohn's disease (Crohn's III)"},{"issue":"10","key":"10.1002\/14651858.CD008870-BIB3|cit3","first-page":"581","article-title":"Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn's ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group","volume":"33","author":"Gross","year":"1995","journal-title":"Z Gastroenterol"},{"issue":"2","key":"10.1002\/14651858.CD008870-BIB4|cit4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000200228","article-title":"Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease","volume":"45","author":"Mahida","year":"1990","journal-title":"Digestion"},{"issue":"10","key":"10.1002\/14651858.CD008870-BIB5|cit5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1055\/s-2008-1068828","article-title":"Successful acute treatment of chronic inflammatory intestinal diseases with oral 5-aminosalicylic acid","volume":"110","author":"Maier","year":"1985","journal-title":"Dtsch Med Wochenschr"},{"issue":"1","key":"10.1002\/14651858.CD008870-BIB6|cit6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1155\/1990\/156847","article-title":"Clinical efficacy of oral mesalamine in Crohn's disease","volume":"4","author":"Maier","year":"1990","journal-title":"Can J Gastroenterol"},{"issue":"2","key":"10.1002\/14651858.CD008870-BIB7|cit7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0016-5085(84)90409-8","article-title":"European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment","volume":"86","author":"Malchow","year":"1984","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD008870-BIB8|cit8","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1155\/1990\/659079","article-title":"Oral 5-ASA versus prednisolone in short term treatment of Crohn's disease: A multicentre controlled trial","volume":"4","author":"Martin","year":"1990","journal-title":"Can J Gastroenterol [Conference Paper]"},{"issue":"3","key":"10.1002\/14651858.CD008870-BIB9|cit9","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0016-5085(99)70172-1","article-title":"Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial","volume":"116","author":"Prantera","year":"1999","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1002\/14651858.CD008870-BIB10|cit10","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3109\/00365528708991929","article-title":"5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa","volume":"22","author":"Rasmussen","year":"1987","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"10.1002\/14651858.CD008870-BIB11|cit11","doi-asserted-by":"crossref","first-page":"445","DOI":"10.7326\/0003-4819-114-6-445","article-title":"Sulphasalazine and prednisone compared with sulphasalazine for treating active Crohn disease. A double-blind, randomized, multicenter trial","volume":"114","author":"Rijk","year":"1991","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1002\/14651858.CD008870-BIB12|cit12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000199279","article-title":"Effect of a slow-release 5'-aminosalicylic acid preparation on disease activity in Crohn's disease","volume":"33","author":"Saverymuttu","year":"1986","journal-title":"Digestion"},{"issue":"7","key":"10.1002\/14651858.CD008870-BIB13|cit13","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1155\/1990\/260563","article-title":"Oral 5-aminosalicylic acid versus 6-methylprednisolone in active Crohn's disease","volume":"4","author":"Scholmerich","year":"1990","journal-title":"Can J Gastroenterol [Conference Paper]"},{"issue":"5","key":"10.1002\/14651858.CD008870-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/0016-5085(93)90337-C","article-title":"Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group","volume":"104","author":"Singleton","year":"1993","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD008870-BIB15|cit15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1542-3565(04)00122-3","article-title":"Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1002\/14651858.CD008870-BIB16|cit16","unstructured":"Nordic Research Inc Clinical research report: efficacy and safety of oral Pentasa in the treatment of active Crohn's disease (Crohn's II)"},{"issue":"2","key":"10.1002\/14651858.CD008870-BIB17|cit17","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/0016-5085(94)90210-0","article-title":"Second trial of mesalamine therapy in the treatment of active Crohn's disease","volume":"107","author":"Singleton","year":"1994","journal-title":"Gastroenterology"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD008870-BIB18|cit18","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","article-title":"National Cooperative Crohn's Disease Study: results of drug treatment","volume":"77","author":"Summers","year":"1979","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD008870-BIB19|cit19","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1056\/NEJM199808063390603","article-title":"A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group","volume":"339","author":"Thomsen","year":"1998","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1002\/14651858.CD008870-BIB20|cit20","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/00004836-199412000-00003","article-title":"A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis","volume":"19","author":"Tremaine","year":"1994","journal-title":"J Clin Gastroenterol"},{"issue":"5","key":"10.1002\/14651858.CD008870-BIB21|cit21","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/gut.22.5.404","article-title":"Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study","volume":"22","author":"Hees","year":"1981","journal-title":"Gut"},{"key":"10.1002\/14651858.CD008870-BIB22|cit22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00054725-199512000-00001","article-title":"A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn's disease","volume":"1","author":"Wright","year":"1995","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1002\/14651858.CD008870-BIB23|cit23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF02774676","article-title":"Salazopyrin in the management of Crohn's disease. The Japanese Research Committee for Crohn's disease","volume":"20","year":"1985","journal-title":"Gastroenterol Jpn"},{"issue":"1","key":"10.1002\/14651858.CD008870-BIB24|cit24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2036.1990.tb00449.x","article-title":"Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. International Mesalazine Study Group","volume":"4","year":"1990","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1002\/14651858.CD008870-BIB25|cit25","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/00365521.1974.12096873","article-title":"The clinical effect of salazosulphapyridine (Salazopyrin r) in Crohn's disease. A controlled double-blind study","volume":"9","author":"Anthonisen","year":"1974","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"10.1002\/14651858.CD008870-BIB26|cit26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00004836-199504000-00008","article-title":"A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission","volume":"20","author":"Arber","year":"1995","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"10.1002\/14651858.CD008870-BIB27|cit27","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1053\/j.gastro.2004.06.051","article-title":"Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease","volume":"127","author":"Ardizzone","year":"2004","journal-title":"Gastroenterology"},{"issue":"Suppl","key":"10.1002\/14651858.CD008870-BIB28|cit28","first-page":"A195","article-title":"The effect of mesalamine (Pentasa) on small bowel Crohn's disease (SBCD) (Abstract)","volume":"100","author":"Barreiro","year":"1991","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD008870-BIB29|cit29","first-page":"104","article-title":"[Drug safety, acceptance and effectiveness of 5-aminosalicylic acid (mesalazine) in the treatment of ulcerative colitis and Crohn disease]","volume":"18","author":"Bayerdorffer","year":"1988","journal-title":"Leber Magen Darm"},{"issue":"7","key":"10.1002\/14651858.CD008870-BIB30|cit30","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/00365521.1976.12097167","article-title":"Postoperative treatment with corticosteroids and salazosulphapyridine (Salazopyrin) after radical resection for Crohn's disease","volume":"11","author":"Bergman","year":"1976","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"10.1002\/14651858.CD008870-BIB31|cit31","first-page":"200","article-title":"5-aminosalicylic acid in the prevention of relapses of Crohn's disease in remission: a long-term study","volume":"11","author":"Bresci","year":"1991","journal-title":"Int J Clin Pharmacol Res"},{"issue":"4","key":"10.1002\/14651858.CD008870-BIB32|cit32","first-page":"133","article-title":"Long-term therapy with 5-aminosalicylic acid in Crohn's disease: is it useful? Our four years experience","volume":"14","author":"Bresci","year":"1994","journal-title":"Int J Clin Pharmacol Res"},{"issue":"2","key":"10.1002\/14651858.CD008870-BIB33|cit33","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00004836-200009000-00012","article-title":"Does the initial location of Crohn's disease have an influence on the time-to-relapse in patients under maintenance treatment with oral mesalamine?","volume":"31","author":"Bresci","year":"2000","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"10.1002\/14651858.CD008870-BIB34|cit34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF01308338","article-title":"Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease","volume":"37","author":"Brignola","year":"1992","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10.1002\/14651858.CD008870-BIB35|cit35","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0016-5085(95)90059-4","article-title":"Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group","volume":"108","author":"Brignola","year":"1995","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD008870-BIB36|cit36","first-page":"60","article-title":"Oral high dose mesalazine treatment in Crohn's disease and ulcerative colitis","volume":"14","author":"Busam","year":"1996","journal-title":"Verdauungskrankheiten"},{"issue":"11","key":"10.1002\/14651858.CD008870-BIB37|cit37","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1097\/00042737-200111000-00006","article-title":"Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy","volume":"13","author":"Campbell","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"10.1002\/14651858.CD008870-BIB38|cit38","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2036.1994.tb00158.x","article-title":"Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC)","volume":"8","author":"Caprilli","year":"1994","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1002\/14651858.CD008870-BIB39|cit39","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1046\/j.1365-2036.2003.01462.x","article-title":"Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial","volume":"17","author":"Caprilli","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1002\/14651858.CD008870-BIB40|cit40","first-page":"P037","article-title":"Prevention of recurrence by mesalamine (PENTASA) in pediatric Crohn's disease. A multicentric double blind trial","volume":"36","author":"Cezard","year":"2003","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"10.1002\/14651858.CD008870-BIB41|cit41","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1572-0241.1999.935_q.x","article-title":"A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID)","volume":"94","author":"Colombel","year":"1999","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1002\/14651858.CD008870-BIB42|cit42","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1046\/j.1365-2036.1997.00212.x","article-title":"Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease","volume":"11","author":"Franchis","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"issue":"50","key":"10.1002\/14651858.CD008870-BIB43|cit43","first-page":"1723","article-title":"[5-Aminosalicylic acid in the prevention of recurrences of Crohn's disease]","volume":"120","author":"Corso","year":"1995","journal-title":"Dtsch Med Wochenschr"},{"issue":"12","key":"10.1002\/14651858.CD008870-BIB44|cit44","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1007\/BF01536700","article-title":"Clinical relapse of Crohn's disease under standardized conservative treatment and after excisional surgery","volume":"34","author":"Dirks","year":"1989","journal-title":"Dig Dis Sci"},{"issue":"10","key":"10.1002\/14651858.CD008870-BIB45|cit45","first-page":"563","article-title":"[Azathioprine and mesalazine in the prevention of postsurgical recurrence of Crohn's disease: a retrospective study.]","volume":"27","author":"Domenech","year":"2004","journal-title":"Gastroenterol Hepatol"},{"key":"10.1002\/14651858.CD008870-BIB46|cit46","first-page":"930","article-title":"[Prevention of recurrence by salazosulfapyridine (azulfidine) therapy in Crohn's disease. A double blind study]","volume":"82 Pt 1","author":"Ewe","year":"1976","journal-title":"Verh Dtsch Ges Inn Med"},{"issue":"4","key":"10.1002\/14651858.CD008870-BIB47|cit47","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000199850","article-title":"Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial","volume":"42","author":"Ewe","year":"1989","journal-title":"Digestion"},{"issue":"3","key":"10.1002\/14651858.CD008870-BIB48|cit48","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00004836-199310000-00009","article-title":"Experience with Eudragit-S-coated mesalamine (Asacol) in inflammatory bowel disease. An open study","volume":"17","author":"Faber","year":"1993","journal-title":"J Clin Gastroenterol"},{"issue":"9-10","key":"10.1002\/14651858.CD008870-BIB49|cit49","first-page":"410","article-title":"[Crohn's disease with predominant lesions in the colon. Prospective long term study of a treatment combining corticosteroids and sulfasalazine with or without azathioprine (author's transl)]","volume":"43","author":"Fiasse","year":"1980","journal-title":"Acta Gastroenterol Belg"},{"issue":"1","key":"10.1002\/14651858.CD008870-BIB50|cit50","first-page":"A11","article-title":"Prevention of Crohn's disease recurrences after intestinal resection with eudragid-l-coated 5-aminosalicylic acid. An interim report of a one year double-blind placebo controlled study (ABSTRACT)","volume":"53","author":"Fiasse","year":"1990","journal-title":"Acta Gastroenterologica Belgica"},{"issue":"3","key":"10.1002\/14651858.CD008870-BIB51|cit51","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00042737-199603000-00008","article-title":"Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID)","volume":"8","author":"Florent","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"10.1002\/14651858.CD008870-BIB52|cit52","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0016-5085(93)90411-5","article-title":"Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID)","volume":"104","author":"Gendre","year":"1993","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD008870-BIB53|cit53","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1055\/s-2001-10708","article-title":"[Therapy of active Crohn disease with Boswellia serrata extract H 15]","volume":"39","author":"Gerhardt","year":"2001","journal-title":"Z Gastroenterol"},{"issue":"1","key":"10.1002\/14651858.CD008870-BIB54|cit54","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00004836-198003000-00012","article-title":"Anti-inflammatory drug treatment of Crohn's disease: a prospective evaluation of 100 consecutively treated patients","volume":"2","author":"Goldstein","year":"1980","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"10.1002\/14651858.CD008870-BIB55|cit55","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/00005176-199308000-00010","article-title":"Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn's disease","volume":"17","author":"Griffiths","year":"1993","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"7","key":"10.1002\/14651858.CD008870-BIB56|cit56","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1023\/A:1005588911207","article-title":"Saccharomyces boulardii in maintenance treatment of Crohn's disease","volume":"45","author":"Guslandi","year":"2000","journal-title":"Dig Dis Sci"},{"issue":"9","key":"10.1002\/14651858.CD008870-BIB57|cit57","first-page":"1343","article-title":"Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group","volume":"88","author":"Hanauer","year":"1993","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1002\/14651858.CD008870-BIB58|cit58","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1053\/j.gastro.2004.06.002","article-title":"Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial","volume":"127","author":"Hanauer","year":"2004","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD008870-BIB59|cit59","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1155\/1993\/729483","article-title":"Comparative trial of remission prophylaxis in quiescent Crohn's disease with oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets","volume":"7","author":"Howaldt","year":"1993","journal-title":"Can J Gastroenterol"},{"issue":"11","key":"10.1002\/14651858.CD008870-BIB60|cit60","first-page":"1949","article-title":"Remaining small bowel endoscopic lesions at surgery have no influence on early anastomotic recurrences in Crohn's disease","volume":"90","author":"Klein","year":"1995","journal-title":"Am J Gastroenterol"},{"issue":"26","key":"10.1002\/14651858.CD008870-BIB61|cit61","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJM198012253032602","article-title":"Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease","volume":"303","author":"Klotz","year":"1980","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1002\/14651858.CD008870-BIB62|cit62","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3109\/00365528109181954","article-title":"The effect of metronidazole and sulfasalazine on the fecal flora in patients with Crohn's disease","volume":"16","author":"Krook","year":"1981","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"10.1002\/14651858.CD008870-BIB63|cit63","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3109\/00365528109182013","article-title":"Clinical effect of metronidazole and sulfasalazine on Crohn's disease in relation to changes in the fecal flora","volume":"16","author":"Krook","year":"1981","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"10.1002\/14651858.CD008870-BIB64|cit64","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/gut.18.1.69","article-title":"Sulphasalazine in asymptomatic Crohn's disease. A multicentre trial","volume":"18","author":"Lennard-Jones","year":"1977","journal-title":"Gut"},{"issue":"4","key":"10.1002\/14651858.CD008870-BIB65|cit65","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/0016-5085(91)90711-S","article-title":"Comparison of enteral nutrition and drug treatment in active Crohn's disease. Results of the European Cooperative Crohn's Disease Study. IV","volume":"101","author":"Lochs","year":"1991","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD008870-BIB66|cit66","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0016-5085(00)70208-3","article-title":"Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI","volume":"118","author":"Lochs","year":"2000","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1002\/14651858.CD008870-BIB67|cit67","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/gut.49.4.552","article-title":"Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study","volume":"49","author":"Mahmud","year":"2001","journal-title":"Gut"},{"issue":"29-30","key":"10.1002\/14651858.CD008870-BIB68|cit68","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1055\/s-2008-1070088","article-title":"[5-Aminosalicylic acid in ulcerative colitis and Crohn's disease (author's transl)]","volume":"107","author":"Maier","year":"1982","journal-title":"Dtsch Med Wochenschr"},{"issue":"3","key":"10.1002\/14651858.CD008870-BIB69|cit69","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/00365521.1990.12067097","article-title":"Feasibility and effectiveness of a defined-formula diet regimen in treating active Crohn's disease. European Cooperative Crohn's Disease Study III","volume":"25","author":"Malchow","year":"1990","journal-title":"Scand J Gastroenterol"},{"issue":"2","key":"10.1002\/14651858.CD008870-BIB70|cit70","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1053\/cgh.2003.50015","article-title":"Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease","volume":"1","author":"Mantzaris","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1002\/14651858.CD008870-BIB71|cit71","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/00042737-200012110-00010","article-title":"6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease","volume":"12","author":"Mate-Jimenez","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"43","key":"10.1002\/14651858.CD008870-BIB72|cit72","first-page":"786","article-title":"Treatment of chronic inflammatory bowel diseases. A study of mesalazine under conditions of practice with more than 1700 patients","volume":"129","author":"May","year":"1987","journal-title":"Munch Med Wochenschr"},{"issue":"2","key":"10.1002\/14651858.CD008870-BIB73|cit73","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/0016-5085(95)90327-5","article-title":"Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease","volume":"109","author":"McLeod","year":"1995","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD008870-BIB74|cit74","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1053\/gast.1996.v110.pm8608877","article-title":"Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives","volume":"110","author":"Modigliani","year":"1996","journal-title":"Gastroenterology"},{"issue":"797","key":"10.1002\/14651858.CD008870-BIB75|cit75","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/pgmj.68.797.189","article-title":"Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis?","volume":"68","author":"Nakshabendi","year":"1992","journal-title":"Postgrad Med J"},{"issue":"Supplement","key":"10.1002\/14651858.CD008870-BIB76|cit76","first-page":"A274","article-title":"Experience with low dose Asacol in inflammatory bowel disease in a community based GI practice","volume":"86","author":"Nichols","year":"1991","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1002\/14651858.CD008870-BIB77|cit77","first-page":"374","article-title":"[Azathioprine and 5-ASA in the prevention of postoperative recurrence of Crohn's disease]","volume":"23","author":"Nos","year":"2000","journal-title":"Gastroenterol Hepatol"},{"issue":"3","key":"10.1002\/14651858.CD008870-BIB78|cit78","first-page":"227","article-title":"A retrospective trial comparing 5-ASA plus ciprofloxacin and metronidazole with 5-ASA and corticosteroids in the treatment of active Crohn's disease","volume":"11","author":"Parlak","year":"2000","journal-title":"Turk J Gastroenterol"},{"issue":"Supplement","key":"10.1002\/14651858.CD008870-BIB79|cit79","first-page":"A239","article-title":"Open-label, prospective study of slow-release 5-aminosalicylic acid 3 g\/day for mild or moderately active Crohn's disease (CD) patients","volume":"100","author":"Piodi","year":"1991","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1002\/14651858.CD008870-BIB80|cit80","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0016-5085(92)90822-G","article-title":"Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group","volume":"103","author":"Prantera","year":"1992","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1002\/14651858.CD008870-BIB81|cit81","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S0016-5085(83)80017-1","article-title":"Treatment of Crohn's disease with peroral 5-aminosalicylic acid","volume":"85","author":"Rasmussen","year":"1983","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD008870-BIB82|cit82","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0016-5085(82)80188-1","article-title":"A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. I. Design and methodologic considerations","volume":"83","author":"Rosen","year":"1982","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD008870-BIB83|cit83","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0016-5085(82)80189-3","article-title":"A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result","volume":"83","author":"Ursing","year":"1982","journal-title":"Gastroenterology"},{"issue":"45","key":"10.1002\/14651858.CD008870-BIB84|cit84","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1055\/s-2008-1069077","article-title":"[Metronidazole in the treatment of Crohn disease. Results of a controlled randomized prospective study]","volume":"110","author":"Schneider","year":"1985","journal-title":"Dtsch Med Wochenschr"},{"issue":"8","key":"10.1002\/14651858.CD008870-BIB85|cit85","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/gut.35.8.1081","article-title":"Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis","volume":"35","author":"Schreiber","year":"1994","journal-title":"Gut"},{"issue":"4 Pt2","key":"10.1002\/14651858.CD008870-BIB86|cit86","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/0016-5085(79)90388-3","article-title":"A trial of sulfasalazine as adjunctive therapy in Crohn's disease","volume":"77","author":"Singleton","year":"1979","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD008870-BIB87|cit87","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/BF02064179","article-title":"Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease","volume":"40","author":"Singleton","year":"1995","journal-title":"Dig Dis Sci"},{"issue":"10","key":"10.1002\/14651858.CD008870-BIB88|cit88","first-page":"721","article-title":"[Basic diet in Crohn's disease]","volume":"131","author":"Stober","year":"1983","journal-title":"Monatsschr Kinderheilkd"},{"issue":"4","key":"10.1002\/14651858.CD008870-BIB89|cit89","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/S0016-5085(97)70117-3","article-title":"A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group","volume":"112","author":"Sutherland","year":"1997","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD008870-BIB90|cit90","first-page":"12","article-title":"Enteral nutrition in the short-term treatment of active inflammatory bowel diseases: A single-centre experience","volume":"19","author":"Terranova","year":"2001","journal-title":"RINPE"},{"issue":"3","key":"10.1002\/14651858.CD008870-BIB91|cit91","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1572-0241.2002.05544.x","article-title":"Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life","volume":"97","author":"Thomsen","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1002\/14651858.CD008870-BIB92|cit92","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1365-2036.1995.tb00438.x","article-title":"Mesalazine (Mesasal\/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease","volume":"9","author":"Thomson","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1002\/14651858.CD008870-BIB93|cit93","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1136\/gut.27.7.814","article-title":"Endotoxaemia in active Crohn's disease. Treatment with whole gut irrigation and 5-aminosalicylic acid","volume":"27","author":"Wellmann","year":"1986","journal-title":"Gut"},{"issue":"Supplement A","key":"10.1002\/14651858.CD008870-BIB94|cit94","first-page":"71A","article-title":"New oral preparations for maintenance therapy in Crohn's disease (abstract)","volume":"2","author":"Wellmann","year":"1988","journal-title":"Can J Gastroenterol"},{"issue":"2","key":"10.1002\/14651858.CD008870-BIB95|cit95","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3109\/00365527809181743","article-title":"The long-term prophylactic effect of salazosulphapyridine (Salazopyrin) in primarily resected patients with Crohn's disease. A controlled double-blind trial","volume":"13","author":"Wenckert","year":"1978","journal-title":"Scand J Gastroenterol"},{"issue":"12","key":"10.1002\/14651858.CD008870-BIB96|cit96","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/gut.15.12.960","article-title":"Effects of sulphasalazine (Salazopyrin) on faecal flora in patients with inflammatory bowel disease","volume":"15","author":"West","year":"1974","journal-title":"Gut"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD008870-BIB97|cit97","doi-asserted-by":"crossref","first-page":"A783","DOI":"10.1016\/S0016-5085(00)85276-2","article-title":"Mesalazine plus adjunctive oligopeptide diet improve health related quality of life as efficacious as conventional steroids in the treatment of mild to moderate acute Crohn's disease","volume":"118","author":"Winterkamp","year":"2000","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1002\/14651858.CD008870-BIB98|cit98","first-page":"613","article-title":"Efficacy of Pentasa tablets for the treatment of inflammatory bowel disease","volume":"102","author":"Wong","year":"2003","journal-title":"J Formos Med Assoc"},{"issue":"8044","key":"10.1002\/14651858.CD008870-BIB99|cit99","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(77)90831-5","article-title":"An experiment to determine the active therapeutic moiety of sulphasalazine","volume":"2","author":"Azad Khan","year":"1977","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD008870-BIB100|cit100","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0016-5085(98)70254-9","article-title":"Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group","volume":"115","author":"Bar-Meir","year":"1998","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD008870-BIB101|cit101","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0016-5085(82)80190-X","article-title":"Incidence and prevalence of ulcerative colitis and Crohn's disease in the County of Copenhagen, 1962 to 1978","volume":"83","author":"Binder","year":"1982","journal-title":"Gastroenterology"},{"issue":"19","key":"10.1002\/14651858.CD008870-BIB102|cit102","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1002\/(SICI)1097-0258(19991015)18:19<2593::AID-SIM392>3.0.CO;2-T","article-title":"Examining the minimum important difference","volume":"18","author":"Brant","year":"1999","journal-title":"Stat Med"},{"issue":"2","key":"10.1002\/14651858.CD008870-BIB103|cit103","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/gut.41.2.209","article-title":"Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group","volume":"41","author":"Campieri","year":"1997","journal-title":"Gut"},{"issue":"2","key":"10.1002\/14651858.CD008870-BIB104|cit104","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/gut.35.2.231","article-title":"Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Th\u00e9rapeutiques des Affections Inflammatoires Digestives","volume":"35","author":"Cellier","year":"1994","journal-title":"Gut"},{"issue":"6","key":"10.1002\/14651858.CD008870-BIB105|cit105","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/gut.15.6.435","article-title":"Short-term course and prognosis of Crohn's disease","volume":"15","author":"Dombal","year":"1974","journal-title":"Gut"},{"issue":"3","key":"10.1002\/14651858.CD008870-BIB106|cit106","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"9","key":"10.1002\/14651858.CD008870-BIB107|cit107","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1136\/gut.2006.093484","article-title":"PPARgamma as a new therapeutic target in inflammatory bowel diseases","volume":"55","author":"Dubuquoy","year":"2006","journal-title":"Gut"},{"issue":"5","key":"10.1002\/14651858.CD008870-BIB108|cit108","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S1542-3565(04)00121-1","article-title":"5-ASA therapy for active Crohn's disease: old friends, old data, and a new conclusion","volume":"2","author":"Feagan","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1002\/14651858.CD008870-BIB109|cit109","first-page":"905","article-title":"Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German\/Austrian Budesonide Study Group","volume":"8","author":"Gross","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"10.1002\/14651858.CD008870-BIB110|cit110","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1572-0241.2001.03671.x","article-title":"Management of Crohn's disease in adults","volume":"96","author":"Hanauer","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1002\/14651858.CD008870-BIB111|cit111","first-page":"81","article-title":"The state of the art in the management of inflammatory bowel disease","volume":"3","author":"Hanauer","year":"2003","journal-title":"Rev Gastroenterol Disord"},{"issue":"5","key":"10.1002\/14651858.CD008870-BIB112|cit112","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1542-3565(04)00122-3","article-title":"Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1002\/14651858.CD008870-BIB113|cit113","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184.ch8","article-title":"Chapter 8: Assessing risk of bias in included studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]","author":"Higgins","year":"2008"},{"issue":"1","key":"10.1002\/14651858.CD008870-BIB114|cit114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"issue":"6","key":"10.1002\/14651858.CD008870-BIB115|cit115","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/j.gastro.2004.01.063","article-title":"Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence and environmental influences","volume":"126","author":"Loftus","year":"2004","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1002\/14651858.CD008870-BIB116|cit116","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1111\/j.1572-0241.2000.03342.x","article-title":"Progress in understanding the mechanisms of action of 5-aminosalicylic acid","volume":"95","author":"MacDermott","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1002\/14651858.CD008870-BIB117|cit117","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.psychres.2004.06.011","article-title":"Assessing publication bias in genetic association studies: evidence from a recent meta-analysis","volume":"129","author":"Munafo","year":"2004","journal-title":"Psychiatry Res"},{"issue":"11","key":"10.1002\/14651858.CD008870-BIB118|cit118","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/gut.28.11.1474","article-title":"Influence of olsalazine on gastrointestinal transit in ulcerative colitis","volume":"28","author":"Rao","year":"1987","journal-title":"Gut"},{"issue":"8","key":"10.1002\/14651858.CD008870-BIB119|cit119","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1084\/jem.20041948","article-title":"Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma","volume":"201","author":"Rousseaux","year":"2005","journal-title":"J Exp Med"},{"issue":"13","key":"10.1002\/14651858.CD008870-BIB120|cit120","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJM199409293311304","article-title":"A comparison of budesonide with prednisolone for active Crohn's disease","volume":"331","author":"Rutgeerts","year":"1994","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1002\/14651858.CD008870-BIB121|cit121","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1111\/j.1572-0241.2002.07092.x","article-title":"Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis","volume":"97","author":"Sandborn","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1002\/14651858.CD008870-BIB122|cit122","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1053\/gast.2002.31072","article-title":"A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease","volume":"122","author":"Sandborn","year":"2002","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1002\/14651858.CD008870-BIB123|cit123","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1046\/j.1365-2036.2003.01661.x","article-title":"Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm","volume":"18","author":"Sandborn","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1002\/14651858.CD008870-BIB124|cit124","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1136\/gut.2003.035253","article-title":"CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial","volume":"53","author":"Sandborn","year":"2004","journal-title":"Gut"},{"issue":"3","key":"10.1002\/14651858.CD008870-BIB125|cit125","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1053\/j.gastro.2005.06.064","article-title":"A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease","volume":"129","author":"Schreiber","year":"2005","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD008870-BIB126|cit126","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1053\/j.gastro.2004.01.024","article-title":"A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease","volume":"126","author":"Su","year":"2004","journal-title":"Gastroenterology"},{"issue":"22","key":"10.1002\/14651858.CD008870-BIB127|cit127","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1056\/NEJM200111293452221","article-title":"A comparison of budesonide and mesalamine for active Crohn's disease. Correction","volume":"345","author":"Thomsen","year":"2001","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1002\/14651858.CD008870-BIB128|cit128","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3109\/00365528309182095","article-title":"Serum antibodies to Bacteroides species in chronic inflammatory bowel disease","volume":"18","author":"Tvede","year":"1983","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"10.1002\/14651858.CD008870-BIB129|cit129","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2165\/00003495-199141040-00009","article-title":"Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease","volume":"41","author":"Wadworth","year":"1991","journal-title":"Drugs"}],"updated-by":[{"DOI":"10.1002\/14651858.cd008870.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,7,3]],"date-time":"2016-07-03T00:00:00Z","timestamp":1467504000000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD008870\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T15:59:54Z","timestamp":1711987194000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD008870"}},"subtitle":[],"editor":[{"given":"Wee-Chian","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,12,8]]},"references-count":129,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008870","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD008870.pub2","asserted-by":"object"}]},"subject":[],"published":{"date-parts":[[2010,12,8]]}}}